Skip to main content
SpringerLink
Log in
Book cover

Cancer Chemoprevention pp 297–304Cite as

Strategies in Lung Cancer Chemoprevention

  • Chapter

  • 834 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Lung cancer is the leading cause of cancer deaths worldwide. It has overtaken breast cancer as the leading cause of cancer death in women, due largely to increased incidence of smoking among women, as well as adolescents of both sexes. Though the relationship between lung cancer and tobacco is well described, smoking cessation efforts have had limited success. Lung cancer incidence for 2002 was estimated to be 174,300; the projected number of deaths was 157,700 (1). Early detection methods have also been largely unsuccessful—no benefit of screening with chest radiographs or CT scans has been demonstrated, although studies are ongoing. Over the past 40 yr, the overall survival rate has improved only slightly as surgery, radiation therapy, and chemotherapy remain the mainstays of current treatment. Therapies with novel targeted agents are currently under active investigation in all settings of treatment. Primary lung cancer prevention efforts focus on educating people not to begin smoking; secondary prevention involves cessation efforts; and chemoprevention targets reversal of premalignant lesions and prevention of second primary tumors (SPTs) in patients with a prior history of cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.

    Article  PubMed  Google Scholar 

  2. Adler I. Primary Malignant Growths of the Lung and Bronchi. Longmans, Green and Co., New York, 1912.

    Google Scholar 

  3. Ochsner A, DeBakey M. Carcinoma of the lung. Arch Surgery 1940:209–258.

    Google Scholar 

  4. Auerbach O, Gere JB, Forman JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1957;256:98–104.

    Google Scholar 

  5. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs 1970–1977. N Engl J Med 1979;300:381–386.

    PubMed  CAS  Google Scholar 

  6. Auerbach O, Stout AP, Hammond EC, et al. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961;265:253–267.

    PubMed  CAS  Google Scholar 

  7. Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992;65:737–743.

    PubMed  CAS  Google Scholar 

  8. Gouveia J, Hercend T, Lemaigre G, et al. Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1982;1:710–712.

    Article  PubMed  CAS  Google Scholar 

  9. Lee JS, Lippman SM, Benner SE, et al. Arandomized placebocontrolled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994;12:937–945.

    PubMed  CAS  Google Scholar 

  10. Mathe G, Gouveia J, Hercend R, et al. Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment. Cancer Detect Prev 1982;5:461–466.

    PubMed  CAS  Google Scholar 

  11. Misset JL, Santelli G, Homasson JP, et al. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev 1986;9:167–170.

    PubMed  CAS  Google Scholar 

  12. Heimberger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: report of a preliminary randomized double-blind intervention trial. JAMA 1988; 259:1525–1530.

    Article  Google Scholar 

  13. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–1505.

    PubMed  CAS  Google Scholar 

  14. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15–20.

    Article  PubMed  CAS  Google Scholar 

  15. Kurie JM, Lotan R, Lee JJ, et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003;95:178–179.

    Article  Google Scholar 

  16. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin Aon lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150–1155.

    Article  PubMed  CAS  Google Scholar 

  17. Goodman M, Morgan RW, Ray R, et al. Cancer in asbestos-exposed occupational cohorts: a meta-analysis. Cancer Causes Control 1999;10:453–465.

    Article  PubMed  CAS  Google Scholar 

  18. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of Vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–1035.

    Article  Google Scholar 

  19. Hennekans CH, Buring JE, Manson JE, et al. Lack of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145–1149.

    Article  Google Scholar 

  20. Decker J, Goldstein JC. Risk factors in head and neck cancer. N Engl J Med 1982;306: 1151–1155.

    PubMed  CAS  Google Scholar 

  21. Wynder EL, Stellman SD. Impact of long-term filter cigarette usage on lung and larynx cancer risk. A case-control study. J Natl Cancer Inst 1979;62:471–477.

    PubMed  CAS  Google Scholar 

  22. Boice JD, Fraumeni JF. Second cancer following cancer of the respiratory system in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985;68:83–98.

    PubMed  Google Scholar 

  23. Gluckman JL, Crissman JD. Survival rates in 548 patients with multiple neoplasms of the upper aerodigestive tract. Laryngoscope 1983;93:71–74.

    PubMed  CAS  Google Scholar 

  24. De Vries N, Snow GB. Multiple primary tumours in laryngeal cancer. J Laryngol Otol 1986; 100:915–918.

    PubMed  Google Scholar 

  25. Yellin A, Hill LR, Benfield JR. Bronchogenic carcinoma associated with upper aerodigestive cancers. J Thorac Cardiovasc Surg 1986;91:674–683.

    PubMed  CAS  Google Scholar 

  26. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328: 184–193.

    Article  PubMed  CAS  Google Scholar 

  27. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932;16:1358–1403.

    Google Scholar 

  28. Vikram B: Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1984;110:564–565.

    Google Scholar 

  29. Lippman SM, Hong WK. Not yet standard: retinoids versus second primary tumors. J Clin Oncol 1993; 11:1204–1207.

    PubMed  CAS  Google Scholar 

  30. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early stage disease. Int J Radiat Oncol Biol Phys 1989;17:691–694.

    PubMed  CAS  Google Scholar 

  31. Larson JT, Adams GL, Fattah HA. Survival statistics for multiple primaries in head and neck cancer. Otolaryngol Head Neck Surg 1990;103:14–24.

    PubMed  CAS  Google Scholar 

  32. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795–801.

    PubMed  CAS  Google Scholar 

  33. Benner SE, Lippman SM, Hong WK. Current status of chemoprevention of head and neck cancer. Oncology 1992;6:61–66.

    PubMed  CAS  Google Scholar 

  34. Benner SE, Pajak TF, Stetz J, et al. Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer. J Natl Cancer Inst 1994;86:1799–1801.

    Article  PubMed  CAS  Google Scholar 

  35. Khuri FR, Lee JJ, Winn RJ, et al. Interim analysis of randomized chemoprevention trial of HNSCC. Proc Annu Meet Am Soc Clin Oncol 1999;abstr 1503.

    Google Scholar 

  36. Kim ES, Khuri FR, Lee JJ, et al. Second primary tumor incidence related to primary index tumor and smoking status in a randomized chemoprevention study of head and neck squamous cell cancer. Proc Ann Meet Am Soc Clin Oncol 2000;19:abstr 1642.

    Google Scholar 

  37. de Vries N, van Zandwijk N, Pastorino U. Chemoprevention of head and neck and lung (pre)cancer. Recent Results Cancer Res 1999;151:13–25.

    PubMed  Google Scholar 

  38. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823–829.

    PubMed  CAS  Google Scholar 

  39. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000;92: 977–986.

    Article  PubMed  Google Scholar 

  40. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 2001;93: 605–618.

    Article  PubMed  CAS  Google Scholar 

  41. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 2001;61:1457–1463.

    PubMed  CAS  Google Scholar 

  42. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000;6:2973–2979.

    PubMed  CAS  Google Scholar 

  43. McLarty JW, Holiday DB, Girard WM, et al. Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995;62:1431S–1438S.

    PubMed  CAS  Google Scholar 

  44. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high dose vitamin A. J Clin Oncol 1993;11:1216–1222.

    PubMed  CAS  Google Scholar 

  45. Bolla M, Lefur R, Ton Van J, et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomized study. Eur J Cancer 1994;30A:767–772.

    Article  PubMed  CAS  Google Scholar 

  46. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996;2:1787–1793.

    PubMed  CAS  Google Scholar 

  47. Vainio H. Chemoprevention of cancer: a controversial and instructive story. Br Med Bull 1999;55: 593–599.

    Article  PubMed  CAS  Google Scholar 

  48. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–1316.

    Article  PubMed  CAS  Google Scholar 

  49. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609–614.

    Article  PubMed  CAS  Google Scholar 

  50. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.

    Article  PubMed  CAS  Google Scholar 

  51. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593–1596.

    PubMed  CAS  Google Scholar 

  52. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138–146.

    Article  PubMed  CAS  Google Scholar 

  53. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58:3761–3764.

    PubMed  CAS  Google Scholar 

  54. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30:73–81.

    Article  PubMed  CAS  Google Scholar 

  55. Watkins DN, Lenzo JC, Segal A, et al. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999;14:412–418.

    Article  PubMed  CAS  Google Scholar 

  56. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997–5001.

    PubMed  CAS  Google Scholar 

  57. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001–1005.

    PubMed  CAS  Google Scholar 

  58. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440–443.

    Article  PubMed  Google Scholar 

  59. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861–867.

    PubMed  CAS  Google Scholar 

  60. Hasturk S, Kemp B, Kalapurakal SK, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2000;94:1023–1031.

    Article  CAS  Google Scholar 

  61. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637–2645.

    Article  PubMed  CAS  Google Scholar 

  62. Berman KS, Verma UN, Harburg G, et al. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res 2002;8:354–360.

    PubMed  CAS  Google Scholar 

  63. Eli Y, Przedecki F, Levin G, et al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol 2001;61:565–571.

    Article  PubMed  CAS  Google Scholar 

  64. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589–1594.

    Article  PubMed  CAS  Google Scholar 

  65. Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000;20:2867–2872.

    PubMed  CAS  Google Scholar 

  66. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6: 2006–2011.

    PubMed  CAS  Google Scholar 

  67. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361–370.

    PubMed  CAS  Google Scholar 

  68. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20,809–20,812.

    Article  PubMed  CAS  Google Scholar 

  69. El-Bayoumy K, Rose DP, Papanikolaou N, et al. Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation. Int J Oncol 2002;20:557–561.

    PubMed  CAS  Google Scholar 

  70. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 2001;15:2742–2744.

    PubMed  CAS  Google Scholar 

  71. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585–591.

    PubMed  CAS  Google Scholar 

  72. Waskewich C, Blumenthal RD, Li H, et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029–2033.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

    Edward S. Kim MD, Faye M. Johnson MD, PhD & Waun Ki Hong MD

  2. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

    Fadlo R. Khuri MD

Authors
  1. Edward S. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faye M. Johnson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Waun Ki Hong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fadlo R. Khuri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Gary J. Kelloff MD

  2. Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Ernest T. Hawk MD, MPH

  3. CCS Associates, Mountain View, CA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Kim, E.S., Johnson, F.M., Hong, W.K., Khuri, F.R. (2005). Strategies in Lung Cancer Chemoprevention. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-768-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-768-0_22

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-077-9

  • Online ISBN: 978-1-59259-768-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation